Background glowHand with small amount of ZORYVE cream on fingertip

Actor portrayal

Background glowHand with small amount of ZORYVE cream on fingertip

Actor portrayal

 Before & After

RELIABLE RESULTS WHEREVER PATIENTS NEED IT

 

ZORYVE cream. Once a day. Anywhere.

Review clinical trial photos of patients with plaque psoriasis treated with ZORYVE

KNEE7

AGE 59, FEMALE

Actual clinical trial patient

Baseline IGA = 3

Knee before treatment - Baseline IGA = 3
Knee - Week 2 IGA = 2
Knee - Week 4 IGA = 2
Knee - Week 6 IGA = 1
Knee - Week 8 IGA = 1

INFRAMAMMARY CREASE7

AGE 59, FEMALE

Actual clinical trial patient

Baseline I-IGA = 2

Inframammary Crease before treatment - Baseline I-IGA = 2
Inframammary Crease - Week 2 I-IGA = 2
Inframammary Crease - Week 4 I-IGA = 1
Inframammary Crease - Week 6 I-IGA = 0
Inframammary Crease - Week 8 I-IGA = 0
 

POWERFUL CLEARANCE IN HARD-TO-TREAT AREAS1

ELBOW7

AGE 58, MALE

Actual clinical trial patient

Baseline IGA = 4

Elbow before treatment - Baseline IGA = 4
Elbow - Week 2 IGA = 3
Elbow - Week 4 IGA = 2
Elbow - Week 6 IGA = 2
Elbow - Week 8 IGA = 1

HEEL7

AGE 53, FEMALE

Actual clinical trial patient

Baseline IGA = 3

Heel before treatment - Baseline IGA = 3
Heel - Week 2 IGA = 1
Heel - Week 4 IGA = 1
Heel - Week 6 IGA = 0
Heel - Week 8 IGA = 1

SHIN7

AGE 61, FEMALE

Actual clinical trial patient

Baseline IGA = 3

Shin before treatment - Baseline IGA = 3
Shin - Week 2 IGA = 2
Shin - Week 4 IGA = 1
Shin - Week 6 IGA = 0
Shin - Week 8 IGA = 0

6x more patients with knee or elbow involvement achieved IGA of Clear (0) or Almost Clear (1) with ZORYVE (49%, n=446) vs vehicle (8%, n=226)11

 
 

CLEARANCE ANYWHERE PATIENTS NEED IT7

FACE & NECK7

AGE 54, MALE

Actual clinical trial patient

Baseline IGA = 3

Face & Neck before treatment - Baseline IGA = 3
Face & Neck - Week 2 IGA = 2
Face & Neck - Week 4 IGA = 1
Face & Neck - Week 6 IGA = 0
Face & Neck - Week 8 IGA = 1

AXILLA7

AGE 60, MALE

Actual clinical trial patient

Baseline I-IGA = 3

Axilla before treatment - Baseline I-IGA = 3
Axilla - Week 2 I-IGA = 3
Axilla - Week 4 I-IGA = 2
Axilla - Week 6 I-IGA = 0
Axilla - Week 8 I-IGA = 0

AXILLA7

AGE 37, MALE

Actual clinical trial patient

Baseline I-IGA = 3

Axilla before treatment - Baseline I-IGA = 3
Axilla - Week 2 I-IGA = 1
Axilla - Week 4 I-IGA = 0
Axilla - Week 6 I-IGA = 0
Axilla - Week 8 I-IGA = 0

3 out of 4 patients achieved I-IGA of Clear (0) or Almost Clear (1) in intertriginous areas with ZORYVE (75%, n=116) vs vehicle (23%, n=63)7

 
 

Meaningful clearance at Week 8

These patients met 2-grade improvement on IGA score but did not achieve Clear (0) or Almost Clear (1) at Week 8.7

KNEE7

AGE 60, MALE

Actual clinical trial patient

Baseline IGA = 4

Knee before treatment - Baseline IGA = 4
Knee - Week 8 IGA = 2

Week 8 IGA = 2

HAND7

AGE 50, MALE

Actual clinical trial patient

Baseline IGA = 4

Hand before treatment - Baseline IGA = 4
Hand - Week 8 IGA = 2

Week 8 IGA = 2

Did you know? Banner ImageDid you know? Banner Image

In a 2021 survey of >500 plaque psoriasis patients, more than 4 OUT OF 5 TOPICAL USERS (81%) wished they had more topical treatment alternatives to steroids.7*

*This survey was conducted online by The Harris Poll on behalf of Arcutis Biotherapeutics among US adults 18+ who have been diagnosed with psoriasis by a healthcare provider. The survey was conducted in 2021, among 507 plaque psoriasis patients. Figures were weighted where necessary to bring the data into line with actual proportions in the population using a multistep weighting process.

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.1

See the Clearance Data
Learn About
The Formulation
Request a Representative